Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Rx Funding Will Exceed $400 Bil., Breaux Predicts; War No Obstacle

Executive Summary

Senate Medicare Rx legislation is likely to exceed the $400 bil. in funding set aside for the program by President Bush, Sen. John Breaux (D-La.) told the Pharmaceutical Research & Manufacturers of America annual meeting March 28 in Naples, Fla

You may also be interested in...



Medicaid Reform Should Be PhRMA Priority, HHS Secretary Thompson Says

Passage of a Medicaid reform bill would do more to improve the pharmaceutical industry's image than a Medicare prescription drug benefit, HHS Secretary Thompson maintained during the PhRMA annual meeting in Naples, Fla. March 29

Rx Industry Must Take Phase IV “Seriously,” Commissioner Tells PhRMA

Pharmaceutical manufacturers need to step up their commitment to postmarketing surveillance and studies, FDA Commissioner McClellan told the Pharmaceutical Research & Manufacturers of America March 28 in Naples, Fla

White House Medicare Rx Draft Proposes “Enhanced” Fee For Service Option

The Bush Administration is considering an "enhanced" fee-for-service Medicare program that would offer a prescription drug benefit for seniors beginning in 2006

UsernamePublicRestriction

Register

PS041574

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel